{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:31:55Z","timestamp":1761708715602},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/wco.0b013e32834a94b6","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T23:42:45Z","timestamp":1317771765000},"page":"484-490","source":"Crossref","is-referenced-by-count":30,"title":["Toxic neuropathy"],"prefix":"10.1097","volume":"24","author":[{"given":"Hadi","family":"Manji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210206","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11910-009-0011-z","article-title":"Update on medication induced peripheral neuropathy.","volume":"9","author":"Weimer","year":"2009","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R2-12-20210206","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy.","volume":"13","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"R3-12-20210206","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1172\/JCI1130","article-title":"Cisplatin induced apoptosis in rat dorsal root ganglion neurones is associated with attempted entry into the cell cycle.","volume":"101","author":"Gill","year":"1998","journal-title":"J Clin Invest"},{"key":"R4-12-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2202-10-77","article-title":"Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of cisplatin-induced neuropathy.","volume":"10","author":"Yoon","year":"2009","journal-title":"BMC Neurosci"},{"key":"R5-12-20210206","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mus.10559","article-title":"Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.","volume":"29","author":"Lehky","year":"2004","journal-title":"Muscle Nerve"},{"key":"R6-12-20210206","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage.","volume":"34","author":"Argyriou","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R7-12-20210206","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.","volume":"132","author":"Park","year":"2009","journal-title":"Brain"},{"key":"R8-12-20210206","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"R9-12-20210206","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy and molecular correlations with response and neuropathy.","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-12-20210206","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib and thalidomide induced peripheral neuropathy.","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"R11-12-20210206","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisolone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"R12-12-20210206","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1182\/blood.V112.11.2646.2646","article-title":"Proteasome inhibitor associated neuropathy is mechanism based.","volume":"112","author":"Silverman","year":"2008","journal-title":"Blood"},{"key":"R13-12-20210206","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"key":"R14-12-20210206","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide: a prospective study.","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"key":"R15-12-20210206","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4065\/79.7.875","article-title":"Thalidomide for patients with relapsed multiple myeloma after high dose chemotherapy and stem cell transplantation: results of open label multicentre phase 2 study of efficacy, toxicity and biological activity.","volume":"79","author":"Richardson","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R16-12-20210206","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicentre, randomised, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.","volume":"26","author":"Rajukumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-12-20210206","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisolone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 0101 trial.","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R18-12-20210206","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment related peripheral neuropathy in multiple myeloma: the challenge continues.","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"R19-12-20210206","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"R20-12-20210206","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"R21-12-20210206","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicentre, phase 1, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsedrefractory multiple myeloma.","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"R22-12-20210206","first-page":"CD005228","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds review.","volume":"2","author":"Albers","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-12-20210206","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.0b013e3181d5279e","article-title":"Vitamin E neuroprotection for cisplatin neuropathy: a randomised, placebo-controlled trial.","volume":"74","author":"Pace","year":"2010","journal-title":"Neurology"},{"key":"R24-12-20210206","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ejpain.2010.08.006","article-title":"Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model.","volume":"15","author":"Kawashiri","year":"2011","journal-title":"Eur J Pain"},{"key":"R25-12-20210206","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pain.2010.10.015","article-title":"Allopregnanolone prevents and suppresses oxaliplatin evoked painful neuropathy: multiparametric assessment and direct evidence.","volume":"152","author":"Meyer","year":"2011","journal-title":"Pain"},{"key":"R26-12-20210206","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pain.2010.10.030","article-title":"Intraepidermal nerve fibre loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline.","volume":"152","author":"Boyette-Davis","year":"2011","journal-title":"Pain"},{"key":"R27-12-20210206","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurtoxicity assessment: a critical revision of the currently available tools.","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"key":"R28-12-20210206","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1529-8027.2009.00214.x","article-title":"CI-Perinoms: chemotherapy induced, peripheral neuropathy outcome measures study.","volume":"14","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"R29-12-20210206","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanism of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65GMMG-HD4 trial.","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"key":"R30-12-20210206","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/annonc\/mdn698","article-title":"Relationship between GST1Ile105Val polymorphism and doxetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity.","volume":"20","author":"Mir","year":"2009","journal-title":"Ann Oncol"},{"key":"R31-12-20210206","doi-asserted-by":"crossref","first-page":"729","DOI":"10.5414\/CPP48729","article-title":"Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of ERCC1 and GSTP1 genes.","volume":"48","author":"Inada","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R32-12-20210206","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/01.aids.0000180786.02930.a1","article-title":"Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.","volume":"19","author":"Hulgan","year":"2005","journal-title":"AIDS"},{"key":"R33-12-20210206","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/aid.2007.0168","article-title":"Cytokine genotype suggests a role for inflammation in nucleoside analogue-associated sensory neuropathy (NRTI-SN) and predicts an individuals NRTI-SN risk.","volume":"2","author":"Cherry","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R34-12-20210206","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/aid.2008.0045","article-title":"Can we predict neuropathy before Stavudine prescription in a resource-limited setting.","volume":"24","author":"Affandi","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R35-12-20210206","first-page":"309","article-title":"Alcohol-related peripheral neuropathy: nutritional, toxic or both Muscle N","volume":"43","author":"Mellion","year":"2010","journal-title":"erve"},{"key":"R36-12-20210206","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mph.0000172751.06286.5b","article-title":"Itraconazole related vincristine neurotoxicity: case report and review of the literature.","volume":"27","author":"Bermudez","year":"2005","journal-title":"Pediatr Hematol Oncol"},{"key":"R37-12-20210206","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000140466","article-title":"Voriconazole-induced neuropathy.","volume":"54","author":"Aksoy","year":"2008","journal-title":"Chemotherapy"},{"key":"R38-12-20210206","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1752-1947-5-140","article-title":"Itraconazole associated quadriparesis and edema: a case report.","volume":"5","author":"Karadi","year":"2011","journal-title":"J Med Case Rep"},{"key":"R39-12-20210206","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1742-6723.2009.01262.x","article-title":"Peripheral neuropathy following nitrous oxide abuse.","volume":"22","author":"Richardson","year":"2010","journal-title":"Emerg Med Australas"},{"key":"R40-12-20210206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1108\/17459265200800022","article-title":"Nitrous oxide: recreational use, regulation and harm reduction.","volume":"8","author":"Jay","year":"2008","journal-title":"Drug Alcohol Today"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0b013e32834a94b6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T08:09:27Z","timestamp":1712995767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-201110000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32834a94b6","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}